Latest Conference Articles

With potential lung cancer nodules sometimes slipping through the cracks, educating stakeholders about artificial intelligence (AI) that can catch nodules early could be helpful in cancer treatment.

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.

Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial, according to Brian Slomovitz, MD, one of the investigators.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Developments in artificial intelligence (AI) can help clinicians to diagnose thoracic conditions that may be miss on first glance.

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.

The value of the combination of albuterol/budesonide is high due to its alleviating of corticosteroid burden, according to Reynold Panettieri Jr, MD.

Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre, discusses a novel adjuvant treatment approach for patients with locally advanced cutaneous squamous cell carcinoma (CSCC).

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.

The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, explains James Chalmers, MD, University of Dundee.

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.

MATTERHORN shows durvalumab enhances survival in early-stage gastric and GEJ cancer, revolutionizing treatment approaches for patients.

Molecular testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, significantly improving disease-free survival rates post-surgery.

An ASCO session on quality services shows how patient and caregiver engagement is crucial to gain better outcomes and cost savings from symptom monitoring efforts.

Different dosages of brensocatib proved effective in treating people living with bronchiectasis when studied in the ASPEN trial.

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking financial stability and patient access to care.

Vincent Picozzi, MD, medical oncologist and director of the Pancreaticobiliary Program at Virginia Mason, discusses findings from the PANOVA-3 trial, which represents a significant breakthrough in locally advanced pancreatic cancer (LA-PAC) treatment.

Studies presented at ASCO reveal promising treatments for triple-negative and ER-positive breast cancer, highlighting the benefits of sacituzumab govitecan and vepdegestrant.

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida, discusses a groundbreaking clinical trial for non-small cell lung cancer (NSCLC) brain metastases.

The pulmonary arterial hypertension (PAH) drug preserved its safety profile at 2.5 years of treatment and continued to reduce mortality compared with placebo.

Exploring caregiver dependence and social determinants of health reveals critical barriers to HIV care for children, impacting treatment adherence and access, explains Priscilla Tsondai, MD, MPH.

Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers Cancer Institute, anticipates groundbreaking data at the American Society of Clinical Oncology (ASCO) 2025 meeting, with plenary sessions spotlighting research that could immediately impact cancer care.

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the roots of the condition.

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven therapies, revolutionizing cancer treatment and diagnostics.